Announced Sat, 11 Jul · 10:26 IST
Emcure subsidiary Gennova sells mRNA unit for Rs 1,395 mn
Strategic Transactions View source PDF
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+0.1%1-day move
₹1810.40
prior close
₹1809.10
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.1+0.8+1.1+0.5+0.1-1.0-0.6-1.4+2.9+3.9————
Up moveDown movePending
AI summary
Emcure's subsidiary Gennova Biopharmaceuticals will sell its mRNA business to Immunoscript Life Science for Rs 1,395 million cash via slump sale. The mRNA unit contributed only 0.71% to FY26 consolidated revenue (Rs 647.10 million). Deal expected to close by July 17. Part of Gennova's strategic refocus on biosimilars and core biotech areas.
Likely market impact
Minor unit (under 1% of revenue) divested for cash. Lets Gennova focus on core biosimilars. No change in Emcure shareholding.